Journal ArticleDOI
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.
Theodoros D. Karamitsos,Stefan K. Piechnik,Sanjay M Banypersad,Marianna Fontana,Ntobeko A.B. Ntusi,Vanessa M Ferreira,Vanessa M Ferreira,Carol J. Whelan,Saul G. Myerson,Matthew D. Robson,Philip N. Hawkins,Stefan Neubauer,James C. Moon +12 more
TLDR
Noncontrast T1 mapping has high diagnostic accuracy for detecting cardiac AL amyloidosis, correlates well with markers of systolic and diastolic dysfunction, and is potentially more sensitive for detecting early disease than LGE imaging.Abstract:
Objectives This study sought to explore the potential role of noncontrast myocardial T1 mapping for detection of cardiac involvement in patients with primary amyloid light-chain (AL) amyloidosis. Background Cardiac involvement carries a poor prognosis in systemic AL amyloidosis. Late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) is useful for the detection of cardiac amyloid, but characteristic LGE patterns do not always occur or they appear late in the disease. Noncontrast characterization of amyloidotic myocardium with T1 mapping may improve disease detection. Furthermore, quantitative assessment of myocardial amyloid load would be of great value. Methods Fifty-three AL amyloidosis patients (14 with no cardiac involvement, 11 with possible involvement, and 28 with definite cardiac involvement based on standard biomarker and echocardiographic criteria) underwent CMR (1.5-T) including noncontrast T1 mapping (shortened modified look-locker inversion recovery [ShMOLLI] sequence) and LGE imaging. These were compared with 36 healthy volunteers and 17 patients with aortic stenosis and a comparable degree of left ventricular hypertrophy as the cardiac amyloid patients. Results Myocardial T1 was significantly elevated in cardiac AL amyloidosis patients (1,140 ± 61 ms) compared to normal subjects (958 ± 20 ms, p Conclusions Noncontrast T1 mapping has high diagnostic accuracy for detecting cardiac AL amyloidosis, correlates well with markers of systolic and diastolic dysfunction, and is potentially more sensitive for detecting early disease than LGE imaging. Elevated myocardial T1 may represent a direct marker of cardiac amyloid load. Further studies are needed to assess the prognostic significance of T1 elevation.read more
Citations
More filters
Journal ArticleDOI
Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)
Daniel Messroghli,James C. Moon,Vanessa M Ferreira,Lars Grosse-Wortmann,Taigang He,Peter Kellman,Julia Mascherbauer,Reza Nezafat,Michael Salerno,Erik B. Schelbert,Andrew J. Taylor,Richard B. Thompson,Martin Ugander,Ruud B. van Heeswijk,Matthias G. Friedrich +14 more
TL;DR: This document provides a summary of the existing evidence for the clinical value of parametric mapping in the heart as of mid 2017, and gives recommendations for practical use in different clinical scenarios for scientists, clinicians, and CMR manufacturers.
Journal ArticleDOI
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Paul A. Heidenreich,Biykem Bozkurt,David Aguilar,Larry A. Allen,Joni J. Byun,Monica Colvin,Anita Deswal,Mark H. Drazner,Shannon M. Dunlay,Linda R. Evers,James C. Fang,Savitri Fedson,Gregg C. Fonarow,Salim S. Hayek,Adrian F. Hernandez,Prateeti Khazanie,Michelle M. Kittleson,Christopher S. Lee,Mark S. Link,Carmelo A. Milano,Lorraine C. Nnacheta,Alexander T. Sandhu,Lynne W. Stevenson,Orly Vardeny,Amanda R. Vest,Clyde W. Yancy +25 more
TL;DR: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" as discussed by the authors provides patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.
Journal ArticleDOI
Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement
James C. Moon,Daniel Messroghli,Peter Kellman,Stefan K. Piechnik,Matthew D. Robson,Martin Ugander,Peter D. Gatehouse,Andrew E. Arai,Matthias G. Friedrich,Stefan Neubauer,Jeanette Schulz-Menger,Jeanette Schulz-Menger,Erik B. Schelbert +12 more
TL;DR: This document provides recommendations for clinical and research T1 and ECV measurement, based on published evidence when available and expert consensus when not, and addresses controversies in the field.
Journal ArticleDOI
T1-mapping in the heart: accuracy and precision
Peter Kellman,Michael S. Hansen +1 more
TL;DR: The technical aspects of key T1-mapping methods and imaging protocols are described and their limitations including the factors that influence their accuracy, precision, and reproducibility are described.
Journal ArticleDOI
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
TL;DR: The 2022 guideline as discussed by the authors provides patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure, with the intent to improve quality of care and align with patients' interests.
References
More filters
Journal ArticleDOI
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Robert O. Bonow,Blase A. Carabello,Kanu Chatterjee,Antonio C. de Leon,David P. Faxon,Michael D. Freed,William H. Gaasch,Bruce W. Lytle,Rick A. Nishimura,Patrick T. O'Gara,Robert A. O'Rourke,Catherine M Otto,Pravin M. Shah,Jack S. Shanewise +13 more
TL;DR: Sidney C. Smith, Jr., MD, FACC, FAHA, Chair as mentioned in this paper, Chair and Alice K. Jacobs, MD, FDAC, FAH, Vice-Chair, Chair and Michael M. Krumholz, MD.
Journal ArticleDOI
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
Morie A. Gertz,Raymond L. Comenzo,Rodney H. Falk,Jean Paul Fermand,Bouke P. C. Hazenberg,Philip N. Hawkins,Giampaolo Merlini,Philippe Moreau,Pierre Ronco,Vaishali Sanchorawala,Orhan Sezer,Alan Solomon,Giles Grateau +12 more
TL;DR: A consensus panel was convened comprising 13 specialists actively involved in the treatment of patients with amyloidosis, and a consensus was developed defining each organ involved and the criteria for response.
Journal Article
Primary systemic amyloidosis : clinical and laboratory features in 474 cases
Robert A. Kyle,Morie A. Gertz +1 more
Journal ArticleDOI
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
Alicia M. Maceira,Jayshree Joshi,Sanjay K Prasad,James C. Moon,Enrica Perugini,Idris Harding,Mary N. Sheppard,Philip A. Poole-Wilson,Philip N. Hawkins,Dudley J. Pennell +9 more
TL;DR: In cardiac amyloidosis, CMR shows a characteristic pattern of global subendocardial late enhancement coupled with abnormal myocardial and blood-pool gadolinium kinetics and may prove to have value in diagnosis and treatment follow-up.
Journal ArticleDOI
Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis Preliminary Validation in Humans
Andrew S. Flett,Martin Hayward,Michael Ashworth,Michael S. Hansen,Andrew M. Taylor,Perry M. Elliott,Christopher G.A. McGregor,James C. Moon +7 more
TL;DR: A robust and noninvasive technique, equilibrium contrast CMR (EQ–CMR), is developed and validated to measure diffuse myocardial fibrosis as an add-on to a standard CMR scan, which allows for the nonin invasive quantification of the diffuse fibrosis burden in myocardIAL diseases.